Cargando…

A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer

Detalles Bibliográficos
Autores principales: Guo, Yuchen, Zhou, Yangyang, Qin, Wenxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Compuscript 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832958/
https://www.ncbi.nlm.nih.gov/pubmed/34708999
http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0520
_version_ 1784648821821669376
author Guo, Yuchen
Zhou, Yangyang
Qin, Wenxin
author_facet Guo, Yuchen
Zhou, Yangyang
Qin, Wenxin
author_sort Guo, Yuchen
collection PubMed
description
format Online
Article
Text
id pubmed-8832958
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Compuscript
record_format MEDLINE/PubMed
spelling pubmed-88329582022-03-01 A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer Guo, Yuchen Zhou, Yangyang Qin, Wenxin Cancer Biol Med Editorial Compuscript 2022-02-15 2021-10-28 /pmc/articles/PMC8832958/ /pubmed/34708999 http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0520 Text en Copyright: © 2022, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0 (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle Editorial
Guo, Yuchen
Zhou, Yangyang
Qin, Wenxin
A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer
title A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer
title_full A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer
title_fullStr A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer
title_full_unstemmed A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer
title_short A CRISPR-Cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer
title_sort crispr-cas9 screen shows the combination efficacy of lenvatinib plus epidermal growth factor receptor inhibitors for treatment of liver cancer
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832958/
https://www.ncbi.nlm.nih.gov/pubmed/34708999
http://dx.doi.org/10.20892/j.issn.2095-3941.2021.0520
work_keys_str_mv AT guoyuchen acrisprcas9screenshowsthecombinationefficacyoflenvatinibplusepidermalgrowthfactorreceptorinhibitorsfortreatmentoflivercancer
AT zhouyangyang acrisprcas9screenshowsthecombinationefficacyoflenvatinibplusepidermalgrowthfactorreceptorinhibitorsfortreatmentoflivercancer
AT qinwenxin acrisprcas9screenshowsthecombinationefficacyoflenvatinibplusepidermalgrowthfactorreceptorinhibitorsfortreatmentoflivercancer
AT guoyuchen crisprcas9screenshowsthecombinationefficacyoflenvatinibplusepidermalgrowthfactorreceptorinhibitorsfortreatmentoflivercancer
AT zhouyangyang crisprcas9screenshowsthecombinationefficacyoflenvatinibplusepidermalgrowthfactorreceptorinhibitorsfortreatmentoflivercancer
AT qinwenxin crisprcas9screenshowsthecombinationefficacyoflenvatinibplusepidermalgrowthfactorreceptorinhibitorsfortreatmentoflivercancer